Results 121 to 130 of about 315,361 (205)

Antibody-Drug Conjugates (ADCs): A Review of Structural Design, Technological Evolution, and Future Perspectives. [PDF]

Molecules
Wu G, Yuan Z, Chen M, Tang X, Wang F, Zhang D.   +5 more
europepmc   +1 more source

Antibody conjugation of paclitaxel enables aqueous compatibility and enhances tumor-targeted efficacy <i>in vitro</i> and <i>in vivo</i>. [PDF]

Front Pharmacol
Rana GE, Yang S, He Y, Qiu C, Long J, Huang Y, Liu W, Luo J, Zhu J, Xu S, Wang Q, Wang CH.   +11 more
europepmc   +1 more source

Impact of afucosylation strategy on antibody function: a comparative study of glycoengineered anti-CD20 antibodies Obinutuzumab and Obinutuzumab beta. [PDF]

MAbs
Shuang Q, Sun M, Lin G, Zhang L, Huang S, Shen Q, Jiang L, Yang L, Sun J, Chen H, Li F, Li J.   +11 more
europepmc   +1 more source

A Moderate-Affinity Antibody-Drug Conjugate Targeting B7-H3 Exerts Potent Antitumor Efficacy. [PDF]

Pharmaceuticals (Basel)
Zhang Z, Zong H, Li Z, Wang S, Xiao X, Xie Y, Zhu J.   +6 more
europepmc   +1 more source

Selective Depletion of Autoreactive Plasma Cells as a Novel Strategy to Treat Acetylcholine Receptor Antibody-Positive Myasthenia Gravis. [PDF]

Eur J Immunol
Khodadadi L, Puppe D, Cirillo DS, Martinez-Cingolani C, Klotsche J, Pelz A, Kohler S, Cheng Q, Lazaridis K, Fichtner M, Pille J, Kruglov A, Bondareva M, Alexander T, Radbruch A, Meisel A, Hiepe F.   +16 more
europepmc   +1 more source

Exercise-mobilized lymphocytes enhance antibody-based immunotherapy in multiple myeloma through CD16⁺ NK cell-mediated cytotoxicity. [PDF]

J Transl Med
Chou L, Valenzuela AM, McDougal LM, Baker FL, Katsanis E, Simpson RJ.   +5 more
europepmc   +1 more source

Engineering Bi-Specific CAR-NK Cells to Restore Antibody-Dependent Cellular Cytotoxicity in Solid Tumors. [PDF]

Cells
Chung JY, Kim JE, Cha D, Lee HJ, Verhoeyen E, An HJ, Park JE.   +6 more
europepmc   +1 more source

Overcoming Trastuzumab-Pertuzumab Resistance and Optimizing Sequential Anti-HER2 Therapy in HER2-Positive Metastatic Breast Cancer. [PDF]

Cancers (Basel)
Yamamoto Y.
europepmc   +1 more source

A glycoengineered anti-ROR1 antibody, GE-zilovertamab, selectively enhances antibody-dependent cellular cytotoxicity against chronic lymphocytic leukemia. [PDF]

Antib Ther
Hasan MK, Widhopf Ii G, Kipps TJ.
europepmc   +1 more source

Selection of laboratory assays for reliable assessment of complement-dependent cytotoxicity: impact of assay choice on CDC quantification. [PDF]

Front Immunol
Majeranowski A, Stasiłojć G, Panasiuk N, Okrój M.   +3 more
europepmc   +1 more source